National AI Awards 2025Discover AI's trailblazers! Join us to celebrate innovation and nominate industry leaders.

Nominate & Attend

Co-founder in Residence, Next Generation Therapeutics for Parkinson's Disease

Deep Science Ventures
London
2 weeks ago
Applications closed

Related Jobs

View all jobs

Service Engineer

Controls Engineer

Controls Engineer

Controls Engineer

Controls Engineer

Controls Engineer

ABOUT THE ROLE
At DSV we’re looking for future Founders, entrepreneurially minded individuals with industry-specific technical and commercial domain expertise eager to solve urgent unmet challenges through venture building.
You will join DSV’s venture creation programme as a Founder in Residence and work closely with the DSV team, using our methodology , to spin-out a new company. During the programme, you’ll work on all aspects related to venture creation in this opportunity area, including working out the optimal approach to solve for the desired outcome, building a team and building a viable business case. Once the new venture is incorporated with pre-seed investment from DSV, you and your co-founders will own the majority stake in the business and continue receiving support from the DSV team post-spinout.
The role is full-time, fully remote until venture incorporation and spin-out, after - TBD.
THE OPPORTUNITY AREA
Over 6 million individuals live with Parkinson’s disease (PD) today, and this number is projected to reach 12 million globally by 2040 as populations age. Whilst current therapies do offer symptomatic relief from debilitating motor symptoms, no clinically approved drug intervenes at root cause, meaning disease progression cannot be prevented. In addition, emerging therapeutics which show great promise in animal models of PD often fail to translate in the clinical setting, with even the most successful clinical trials reporting incremental benefit, often capped by dose limiting toxicity.
To address this, we are partnering with Parkinson’s UK to develop precise, next generation therapies which target true disease modifying nodes in previously unimagined ways. As PD is a multi-pathway pathology, spanning oxidative stress, impaired autophagy, mitochondrial dysfunction and neuroinflammation, the efficacy of single pathway approaches is constrained.
OUR APPROACH
We are designing a therapeutic approach that will target master homeostatic regulators which can simultaneously correct numerous PD pathways, changing the course of disease. We believe this has the potential to transform patient lives by slowing, halting or even reversing disease progression. This pathway has been the focus of drug development in the past but not been drugged successfully through classic approaches. We are looking to unlock this through the use of novel modalities and a clever target selection and targeting strategy that has the potential to overcome the many feedback looks regulating this pathway.
WHO SHOULD APPLY
Essential (must-have):
PhD in neuroscience or other field relevant to the project;
Extensive, systems-level knowledge of Parkinson’s disease, including at the cellular and molecular level;
Expertise in oxidative stress and/or neuroprotective pathways;
Experience in cellular, molecular and/or biochemical approaches to drug discovery for CNS disorders;
Experience working in biotech/pharma or an alternative setting which requires strong commercial awareness and understanding of the drug development process;
Entrepreneurial spirit, likely demonstrated through impactful innovation;
You are innovative, creative, and guided by first-principles thinking;
You are highly motivated to create curative solutions for PD patients.
Preferred (nice-to-have):
Broad knowledge of brain-specific drug delivery techniques;
Experience in nucleic acid based payloads (ASO/siRNA/DNA) and delivery techniques;
Track record of high quality publications in the field, or thought leadership in the field;
High level industry experience in either pharma, biotech, scientific start-ups, life sciences consulting, life sciences VC, or have previously been an inventor/contributor on patents, etc.;
Fundraising experience at seed and Series A stages, with established investor contacts.
OUR OFFER
By joining DSV, you’ll be joining a team of operators who have founded companies and led translation of science at some of the most respected universities, charities, funds and government agencies. 2/3 of the team have founded or led a company at C-suite and 65% have a PhD. Our team dedicate several hours every week to each Founder/founding team to provide tailored guidance, resources and feedback covering every aspect of what it takes to successfully launch a new venture from both the tech and commercial perspectives:
We provide optimised, purpose-built, proprietary tools, resources and processes to help create high-impact ventures from scratch, using our venture creation methodology;
We draw on opportunity area specific know-how provided by our Partner organisation - Parkinson's UK - working collaboratively with their team of experts and Advisors;
We provide £250k launch investment (subject to Investment Committee approval) to incorporate the new venture and develop early proof-of-concept data that’s needed to attract high profile VCs as well as non-dilutive grant funding;
We provide guaranteed income of £4,166 per month paid to each Founder-in-Residence as a fixed consultancy fee until the company is launched and the pre-seed investment is secured;
You and the current Founder-in-Residence, together with any additional co-founders, will collectively own a majority equity stake in the company;
We provide continuous support after post spin-out, including fundraising, commercial partnerships, recruitment and team-building (amongst other things); plus
There are dozens of Founders currently at DSV across sectors working collaboratively and supporting one another - a unique resource to draw on.
WHO YOU'LL BE JOINING
You will be joining Dr. Kiren Baines-Mortimore, an accomplished scientific leader with many years of experience across drug discovery and development. Kiren, is the former co-founder and CSO at Extracellular, a cultivated meat CDMO. Prior to founding Extracellular, Kiren was the Analytical Development and Quality Control Lead at eXmoor Pharma,where she supported clients in the cell and gene therapy sector with process and analytical development, manufacturing, and commercialization. Earlier in her career, Kiren contributed to drug discovery initiatives at Charles River Laboratories. Kiren earned her PhD in Cell Biology from the University of Bristol. Kiren’s background in Parkinson’s combined with her expertise in drug development, along with her outstanding professionalism and ambition, makes her a top talent to work with.
ABOUT DSV
Deep Science Ventures is creating a future in which both humans and the planet can thrive.
We use our unique venture creation process to create, spin-out and invest into science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures.
We operate in 4 sectors: Pharmaceuticals, Climate, Agriculture and Computation, tackling the challenges defining those areas by taking a first principles approach and partnering with leading institutions.
ABOUT OUR PARTNERSHIP WITH PARKINSON'S UK
In a landmark collaboration that marries scientific prowess with an unwavering dedication to improving patient lives, Deep Science Ventures, an avant-garde venture creator headquartered in London, has announced a pioneering partnership with Parkinson’s UK , the leading charity driving better care, treatments, and quality of life for those affected by Parkinson’s.
This strategic alliance is set to merge DSV’s unique invention method with Parkinson’s UK’s rich insights into patient care, igniting the creation of a new, dedicated company. The aim is to propel the most innovative and efficient therapeutic approach into real-world application, funded by the transformative Parkinson’s Virtual Biotech initiative - Parkinson’s UK investment arm.

#J-18808-Ljbffr

National AI Awards 2025

Subscribe to Future Tech Insights for the latest jobs & insights, direct to your inbox.

By subscribing, you agree to our privacy policy and terms of service.

Industry Insights

Discover insightful articles, industry insights, expert tips, and curated resources.

Biotech Jobs Employer Hotlist 2025: 50 UK Companies Actively Hiring Right Now 

Bookmark this guide – we refresh it every quarter so you always know who’s really expanding their life‑science teams. The UK biotechnology scene is on a tear in 2025. Venture & follow‑on funding hit £3.5 billion last year, up 94 % on 2023, and Q1 2025 alone brought in another £924 million of equity for scaling therapeutics, diagnostics & deep‑tech platforms  bioindustry.org. Meanwhile, Westminster’s new industrial strategy pledges a record £86 billion for science & tech, with life sciences top of the eight “high‑growth” priority sectors . The consequence? Hiring is white‑hot. From big‑pharma giants to gene‑editing start‑ups, employers need research scientists, QC analysts, bioprocess engineers, bioinformaticians, regulatory specialists & commercial leads – right now. Below you’ll find 50 organisations that have posted UK vacancies or announced head‑count growth during the past eight weeks. They’re grouped into five bite‑size categories so you can jump straight to the type of employer – & mission – that excites you. For every entry you’ll see: Main UK hub Example recent vacancy Why it’s worth your time (tech, culture, impact) Use the internal search on BiotechnologyJobs.co.uk to pull up live roles, or set a free alert so fresh openings land in your inbox.

Return-to-Work Pathways: Relaunch Your Biotechnology Career with Returnships, Flexible & Hybrid Roles

Returning to work after a career break can feel like stepping into a new frontier—especially in a fast-evolving sector such as biotechnology. Whether you’ve paused your professional journey for parenting, caring responsibilities or another life chapter, the UK’s biotech industry now offers a variety of return-to-work pathways designed to help you transition back smoothly. From formal returnships and part-time contracts to hybrid and fully flexible roles, these programmes acknowledge the value of your transferable skills and life experience. In this guide tailored for parents and carers, you’ll discover how to: Grasp the current demand for biotech talent in the UK Translate your organisational, communication and resilience skills into the laboratory and beyond Tackle common re-entry challenges with practical solutions Refresh your scientific and technical knowledge through targeted learning Access returnship and re-entry programmes specifically in biotech Find roles that fit around family commitments—be they flexible, hybrid or full-time Balance work with caring duties Navigate applications, interviews and networking in the biotech world Learn from inspiring returner success stories Get quick answers in our FAQ section Whether you’re keen to step back into a research lab, quality control, regulatory affairs or bioinformatics team, this article will map out the steps and resources you need to reignite your biotechnology career.

LinkedIn Profile Checklist for Biotechnology Jobs: 10 Tweaks to Skyrocket Recruiter Attention

In the ever-evolving biotechnology industry, showcasing both scientific expertise and collaborative skills on LinkedIn is vital. Recruiters search for candidates skilled in molecular biology, bioinformatics, process development and regulatory affairs—even before roles go live. With dozens of qualified applicants for each position, you need a profile that not only ranks highly in searches but also resonates with biotech hiring teams. This step-by-step LinkedIn for biotechnology jobs checklist presents 10 practical tweaks designed to skyrocket recruiter attention. Whether you’re a recent MSc graduate​, an R&D scientist pivoting into industry, or a seasoned biotech leader targeting your next breakthrough role, these targeted optimisations will highlight your technical prowess and professional narrative.